A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).

Date publication

novembre 2024

Journal

Clinical genitourinary cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr EYMARD Jean-Christophe

Tous les auteurs :
Staehler M, Basso U, Eymard JC, Barthelemy P, Bigot P, Laramas M, Rink M, Suarez C, Guillot A, Bedke J, Hamberg P, De Vivo R, Gajate P, Lázaro-Quintela M, Rastogi P, Perrot V, Qvick B, Dutailly P, Verzoni E, Procopio G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39740313

Résumé

There is a lack of published data on real-world cabozantinib use in patients with advanced renal cell carcinoma after prior vascular endothelial growth factor (VEGF)-targeted therapy.

Mots clés

Adverse event, Dose modification, Targeted therapies, Treatment-refractory renal cell carcinoma, Tyrosine kinase inhibitor

Référence

Clin Genitourin Cancer. 2024 11 30;23(1):102285